Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term extension study of colestilan versus calcium-based phosphate binder in paediatric hyperphosphataemia with chronic kidney disease
2012-002583-27Phase 3Terminated
- Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Start
- Dec 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of colestilan in hyperphosphatemia (2 arms), sponsored by Mitsubishi Tanabe Pharma Corporation. Primary endpoint: Proportion of responders at Week 52 or last observation carried forward. Started Dec 2012; status: terminated.
02
Drugs
colestilan
03
Conditions
hyperphosphatemia
Beyond the preview
Go deeper on 2012-002583-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-002583-27.